Brief: Deciphera Pharmaceuticals Announces Results From CtDNA Analysis From Intrigue Phase 3 Clinical Study

Deciphera Pharmaceuticals

03/01/2023 21:29

Jan 3 (Reuters) - Deciphera Pharmaceuticals Inc
 DCPH.O :
    * DECIPHERA PHARMACEUTICALS ANNOUNCES RESULTS FROM CTDNA
ANALYSIS
FROM INTRIGUE PHASE 3 CLINICAL STUDY DEMONSTRATING SUBSTANTIAL
CLINICAL BENEFIT OF QINLOCK® IN SECOND-LINE GIST PATIENTS WITH
MUTATIONS IN KIT EXON 11 AND 17/18 ONLY
    * DECIPHERA PHARMACEUTICALS INC - COMPANY PLANS TO INITIATE
INSIGHT PIVOTAL PHASE 3 CLINICAL STUDY IN SECOND HALF OF 2023
    * DECIPHERA PHARMACEUTICALS INC - PLANS TO INITIATE INSIGHT
PIVOTAL PHASE 3 CLINICAL STUDY IN SECOND HALF OF 2023
    * DECIPHERA PHARMACEUTICALS INC - OBJECTIVE RESPONSE RATE OF
44.4%
FOR QINLOCK VERSUS 0% FOR SUNITINIB; NOMINAL P VALUE 0.0001

Source text for Eikon:  ID:nBw915PPBa 
Further company coverage:  DCPH.O 
 ((Reuters.Briefs@thomsonreuters.com;))